|Medtronic Expands Availability of Market-Leading Aortic & Peripheral Solutions to U.S. Market|
Recently FDA Approved Valiant Captivia Proximal FreeFlo Tapers for Dissection and TOTAL Across Crossing Support Catheter Featured at the 2014 Vascular Annual Meeting
MINNEAPOLIS -- Jun. 4, 2014 -- Continuing to expand its market-leading portfolio of endovascular solutions, Medtronic, Inc. (NYSE: MDT) announced today that two recently Food and Drug Administration (FDA) approved devices will be featured at the Society for Vascular Surgery's 2014 Vascular Annual Meeting, taking place June 5-7 in Boston. Valiant Captivia Thoracic Stent Graft system proximal FreeFlo tapers line extension now with dissection indication, and the TOTAL across crossing support catheter for peripheral artery disease (PAD) in the below-the-knee (BTK) vessel bed are now available to physicians in the United States.
Valiant Captivia Tapers for Dissection
"There is a growing body of evidence in support of endovascular repair for thoracic aortic dissection as a minimally invasive alternative to open surgical repair and even medical therapy alone," said Joseph Bavaria, MD, professor of surgery and director of the thoracic aortic surgery program at the University of Pennsylvania in Philadelphia, and a national principal investigator for the Medtronic DISSECTION Trial. "The Valiant Captivia system has undoubtedly demonstrated safety and efficacy in the treatment of acute type B dissection cases with excellent technical success."
In January, Medtronic initially introduced its 11 new proximal FreeFlo tapered pieces to the Valiant Captivia system. The expanded size matrix enables physicians to treat thoracic pathologies in tapered aortas, increasing the configuration possibilities by 30 percent to allow for effective treatment of a wider range of patient anatomies. With the addition of dissection indication for the tapers line extension, Medtronic's market-leading thoracic solutions portfolio is now broadly indicated to treat diseases in the thoracic aorta.
"In aortic dissection, the aorta tapers significantly," explained Dr. Jean Panneton, vascular surgery chief and program director at Eastern Virginia Medical School. "The new Valiant Captivia tapered pieces are ideal for treating these challenging cases, because they offer customizable options. This allows optimal graft sizing that can lead to better procedural outcomes for patients with dissected aortas."
TOTAL across crossing support catheter
Dr. Anvar Babaev, interventional cardiologist at NYU Langone Medical Center, performed one of the first U.S. cases with the TOTAL across crossing support catheter.
"Critical limb ischemia with below the knee chronic occlusion is a particularly challenging subset of patients to treat, and this patient was no exception having occluded, severely calcified distal anterior tibial artery and large non-healing foot ulcer," said Dr. Babaev. "I chose to use the TOTAL across crossing support catheter, which enabled successful crossing and recanalization of the very difficult lesion with pushability and support I had not experienced before."
The TOTAL across crossing support catheter expands Medtronic's product portfolio of medical devices used to treat peripheral artery disease (PAD) and is an example of the company's focus on developing innovative lesion-specific solutions for PAD. Along with the Amphirion Plus and Amphirion Deep PTA Balloon Catheters - the addition of TOTAL across crossing support catheter represents a comprehensive solution portfolio for BTK interventions. It is the first of three new products to address the clinical challenge of BTK CLI that Medtronic plans to introduce around the world over the next two years. It is the first of three new products Medtronic plans to introduce that address the clinical challenges associated with the treatment of lower extremity disease.
In collaboration with leading clinicians, researchers and scientists, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular diseases and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers worldwide.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
- end -